CRISPR Therapeutics

CRSPNasdaq Switzerland Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$5.640 B

$58.33 +3.13%

Close of 21 Sept 2026

Revenue

$3.51M

#3339 by revenue

Earnings

-$581.6M

Loss-making

Shares outstanding

96,692,653

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#20CG OncologyCGON$6.94B
#21Scholar RockSRRK$5.87B
#22CRISPR TherapeuticsCRSP$5.64B
#23Iovance BiotherapeuticsIOVA$4.62B
#24Adaptive BiotechnologiesADPT$4.45B

What if CRISPR Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$313,095.70

Per share 5,368× higher

Bitcoin $1.72T

$17,786.29

Per share 305× higher

Nvidia $5.48T

$56,672.95

Per share 972× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for CRISPR Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.